Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.apsb.2021.02.011 http://scihub22266oqcxt.onion/10.1016/j.apsb.2021.02.011 33614402!7883726!33614402     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Acta+Pharm+Sin+B 2021 ; 11 (6): 1555-1567 Nephropedia Template TP {{tp|p=33614402|t=2021. Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase |pdf=|usr=}}{{33614402}} gab.com Text Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase JO: Acta Pharm Sin B http://www.kidney.de/pget.php?&tw=1&pmid=33614402 #FOAvip Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has become one major threat to human population health. The RNA-dependent RNA polymerase (RdRp) presents an ideal target of antivirals, whereas nucleoside analogs inhibitor is hindered by the proofreading activity of coronavirus. Herein, we report that corilagin (RAI-S-37) as a non-nucleoside inhibitor of SARS-CoV-2 RdRp, binds directly to RdRp, effectively inhibits the polymerase activity in both cell-free and cell-based assays, fully resists the proofreading activity and potently inhibits SARS-CoV-2 infection with a low 50% effective concentration (EC(50)) value of 0.13 mumol/L. Computation modeling predicts that RAI-S-37 lands at the palm domain of RdRp and prevents conformational changes required for nucleotide incorporation by RdRp. In addition, combination of RAI-S-37 with remdesivir exhibits additive activity against anti-SARS-CoV-2 RdRp. Together with the current data available on the safety and pharmacokinetics of corilagin as a medicinal herbal agent, these results demonstrate the potential of being developed into one of the much-needed SARS-CoV-2 therapeutics. Twit Text FOAVip Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase ????Acta Pharm Sin B http://www.kidney.de/pget.php?&tw=1&pmid=33614402 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33614402 #FOAvip English Wikipedia <ref>{{Cite pmid|33614402}}</ref> Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase #MMPMID33614402 Li Q; Yi D; Lei X; Zhao J; Zhang Y; Cui X; Xiao X; Jiao T; Dong X; Zhao X; Zeng H; Liang C; Ren L; Guo F; Li X; Wang J; Cen S Acta Pharm Sin B 2021[Jun]; 11 (6): 1555-1567 PMID33614402show ga Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has become one major threat to human population health. The RNA-dependent RNA polymerase (RdRp) presents an ideal target of antivirals, whereas nucleoside analogs inhibitor is hindered by the proofreading activity of coronavirus. Herein, we report that corilagin (RAI-S-37) as a non-nucleoside inhibitor of SARS-CoV-2 RdRp, binds directly to RdRp, effectively inhibits the polymerase activity in both cell-free and cell-based assays, fully resists the proofreading activity and potently inhibits SARS-CoV-2 infection with a low 50% effective concentration (EC(50)) value of 0.13 mumol/L. Computation modeling predicts that RAI-S-37 lands at the palm domain of RdRp and prevents conformational changes required for nucleotide incorporation by RdRp. In addition, combination of RAI-S-37 with remdesivir exhibits additive activity against anti-SARS-CoV-2 RdRp. Together with the current data available on the safety and pharmacokinetics of corilagin as a medicinal herbal agent, these results demonstrate the potential of being developed into one of the much-needed SARS-CoV-2 therapeutics. äCorilagin inhibits SARS-CoV-2 replication by targeting viral RNA-depen(epmc).pdf DeepDyve Pubget Overpricing